BofA lowered the firm’s price target on Bristol Myers (BMY) to $58 from $63 and keeps a Neutral rating on the shares. For Q1, the firm’s total revenue estimates and EPS decline by a low single digit percentage, driven by smaller changes across the product portfolio, but for 2025 its underlying EPS view decreased by 0.5%. For the later 2020’s, the firm’s total revenue estimates decrease by a low single digit percentage, primarily due to lower sales from Camzyos following the failed Phase 3 ODYSSEY trial and Zeposia, the analyst tells investors in a Q1 preview.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Hold Rating on Bristol-Myers Squibb Amid Revenue Challenges and Sector-Wide Valuation Pressures
- Cytokinetics price target lowered to $54 from $62 at BofA
- Bristol-Myers Squibb: Hold Rating Amidst Trial Setbacks and Pipeline Challenges
- Sell Rating for Bristol-Myers Squibb Due to Camzyos Trial Failure and Revenue Pressures
- Bristol-Myers Squibb: Hold Rating Amid Mixed Financial Signals and Future Prospects